Pre-operative Biliary SEMS RCT During Neoadjuvant Therapy

NCT ID: NCT02238847

Last Updated: 2020-02-17

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

119 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-03-24

Study Completion Date

2018-04-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to demonstrate non-inferiority of Fully Covered biliary SEMS to Uncovered biliary SEMS in biliary drainage for the pre-operative management of biliary obstructive symptoms caused by pancreatic cancer in patients undergoing neoadjuvant therapy.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pancreatic Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

WallFlex Biliary RX Fully Covered Stent System

Patients in this group will receive a fully covered study SEMS (self-expanding metal stent)

Reintervention can occur with either a WallFlex™ Biliary RX Fully Covered or Uncovered Stent System

Group Type ACTIVE_COMPARATOR

WallFlex™ Biliary RX Fully Covered/Uncovered Stent System

Intervention Type DEVICE

Reintervention can occur in Arm 1 or Arm 2 with either a WallFlex™ Biliary RX Fully Covered or Uncovered Stent System

WallFlex Biliary RX Uncovered Stent System

Patients in this group will receive an uncovered study SEMS (self-expanding metal stent).

Reintervention can occur with either a WallFlex™ Biliary RX Fully Covered or Uncovered Stent System

Group Type ACTIVE_COMPARATOR

WallFlex™ Biliary RX Fully Covered/Uncovered Stent System

Intervention Type DEVICE

Reintervention can occur in Arm 1 or Arm 2 with either a WallFlex™ Biliary RX Fully Covered or Uncovered Stent System

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

WallFlex™ Biliary RX Fully Covered/Uncovered Stent System

Reintervention can occur in Arm 1 or Arm 2 with either a WallFlex™ Biliary RX Fully Covered or Uncovered Stent System

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 18 or older
* Patient indicated for biliary metal stent placement for the treatment of jaundice and/or cholestasis
* Willing and able to comply with the study procedures and provide written informed consent to participate in the study
* Suspicion of pancreatic adenocarcinoma
* Likely indicated for neoadjuvant treatment
* Distal biliary obstruction consistent with pancreatic cancer
* Location of distal biliary obstruction such that it would allow the proximal end of a stent to be positioned at least 2 cm from the hilum
* Endoscopic and surgical treatment to be provided at the same institution

Exclusion Criteria

* Benign biliary strictures
* Malignancy secondary to Intraductal Papillary Mucinous Neoplasm
* Surgically altered anatomy where ERCP is not possible
* Previous biliary drainage using a SEMS or multiple plastic stents
* Contraindications for endoscopic techniques
* Patients who are currently enrolled in another investigational trial that would directly interfere with the current study
* Pregnancy
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Boston Scientific Corporation

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Yousuke Nakai, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Tokyo University

Dong-Wan Seo, MD

Role: PRINCIPAL_INVESTIGATOR

Asan Medical Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Indiana University Medical Center

Indianapolis, Indiana, United States

Site Status

University of Pittsburgh Medical Center

Pittsburgh, Pennsylvania, United States

Site Status

Virginia Mason Medical Center

Seattle, Washington, United States

Site Status

The Medical College of Wisconsin

Milwaukee, Wisconsin, United States

Site Status

CUB Hopital Erasme

Brussels, , Belgium

Site Status

Centre Hospitalier de l'Université de Montréal-Saint-Luc Hospital

Montreal, Quebec, Canada

Site Status

Fondazione Policlinico Universitario Agostino Gemelli

Rome, , Italy

Site Status

Tokyo University Hospital

Tokyo, , Japan

Site Status

Asan Medical Center

Seoul, , South Korea

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Belgium Canada Italy Japan South Korea

References

Explore related publications, articles, or registry entries linked to this study.

Seo DW, Sherman S, Dua KS, Slivka A, Roy A, Costamagna G, Deviere J, Peetermans J, Rousseau M, Nakai Y, Isayama H, Kozarek R; Biliary SEMS During Neoadjuvant Therapy Study Group. Covered and uncovered biliary metal stents provide similar relief of biliary obstruction during neoadjuvant therapy in pancreatic cancer: a randomized trial. Gastrointest Endosc. 2019 Oct;90(4):602-612.e4. doi: 10.1016/j.gie.2019.06.032. Epub 2019 Jul 2.

Reference Type DERIVED
PMID: 31276674 (View on PubMed)

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

E7034

Identifier Type: OTHER

Identifier Source: secondary_id

90905950

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.